PODD vs ZYME · P/E 34, rev $2.07B vs rev $76.3M
Insulet Corporation (PODD) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported PODD revenue for 2024-12-31 was $2.07B. Net income was $418.3M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
PODD currently screens at market cap $9.94B and trailing P/E 33.5. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the PODD and ZYME stock pages for the full models.
Not investment advice.